On the other hand, SLLP1 could potentially represent a target for an immunologic graft-versus-myeloma effect [26–28] and we cannot exclude the possibility that our observation of a significantly lower expression of SLLP1 after alloSCT is based on a transplant-induced eradication of SLLP1-expressing tumor cells from the patients’ BM. This evidence concerns the gene SPACA3 and plasma cell myeloma.